Value of carnitine therapy in kidney dialysis patients and effects on cardiac function from human and animal studies

Current Drug Targets

Volumn 13, Issue 2, 2012, Pages 285-293

  Molyneux, Rebekah ^a   Seymour, A M ^b   Bhandari, Sunil ^a  

^a HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Cardiac disease; Carnitine; Chronic kidney disease; Dialysis

Indexed keywords

CARNITINE; FATTY ACID;

CARBOHYDRATE METABOLISM; CARDIOMYOPATHY; CARNITINE DEFICIENCY; CELL DEATH; CLINICAL PRACTICE; DRUG MEGADOSE; EXPERIMENTAL MODEL; FATTY ACID OXIDATION; GLOMERULUS; GLYCOLYSIS; HEART ARRHYTHMIA; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART PERFUSION; HEMODIALYSIS PATIENT; HUMAN; KIDNEY; KIDNEY FAILURE; METABOLISM; MITOCHONDRIAL MEMBRANE; MORBIDITY; MORTALITY; MUSCLE FIBRIL; NONHUMAN; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; UREMIA; UREMIC CARDIOMYOPATHY;

CARNITINE; HEART; HUMANS; KIDNEY FAILURE, CHRONIC; MYOCARDIAL ISCHEMIA; MYOCARDIUM; RENAL DIALYSIS;

EID: 84857125287     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012799201595     Document Type: Review

References (93)

1. nd Ed. Oxford Medical Publications 1998; 1885-1918.
2. Parfrey PS, Harnett JD, Foley RN. Heart Failure and ischaemic heart disease. Curr Opin Nephrol Hypertens 1995; 4:105-110.
3. Ninomiya T, Perkovic V, de Galan BE, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2001; 20:1813-1821.
4. Wright RS, Reeder GS, Herzog CA, et al. Acute myocardial infarction and renal dysfunction: A high-risk combination. Ann Intern Med 2002; 137: 563-570.
5. Munoz E, Frazier OH, Taegtmeyer H. Uremic cardiomyopathy: a metabolic hypothesis. J Appl Cardiol 1991; 6: 247-254.
6. Bhandari S. Risk factors and pathophysiology of metabolic change in uraemic cardiac disease. Frontiers in Bioscience (Landmark Edition) 2011; 16: 1364-1387.
7. Lopaschuk GD. Alterations in fatty acid oxidation during reperfusion of the heart after myocardial ischaemia. Am J Cardiol 1997; 80: 11A-16A.
8. Rebouche CJ, Chenard CA. Metabolic fate of dietary carnitine in human adults: Identification and quantification of urinary and faecal metabolites. J Nutr 1991; 121: 539-546.
9. Lopaschuk GD, Belke DD, Gamble J, et al. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochem Biophys Acta 1994; 1213: 263-276.
10. Schonekess BO, Lopaschuk GD. The effects of carnitine on myocardial carbohydrate metabolism. In: de Jong JW, Ferrari R, Eds. The Carnitine System: A New Therapeutical Approach to Cardiovascular Diseases. Dordrecht, Kluwer Academic Publishers 1995; 39-52.
11. Engel AG, Rebouche CJ, Carnitine metabolism and inborn errors. J Inherit Metab Dis 1984; 7 (suppl 1): 38-43.
12. McGarry JD, Brown NF. Mitochondrial carnitine palmitoyl transferase system: from concept to molecular analysis. Eur J Biochem 1997; 244: 1-14.
13. Flanagan JL, Simmons PA, Vehige J, Willcox M, Garret Q. The role of carnitine in disease. Nutrition & Metabolism 2010; 7: 30.
14. Bremer J. Carnitine metabolism and function. Physiol Rev 1983, 63:1421-1480.
15. DeVivo DC, Tein I. Primary and secondary disorders of carnitine metabolism. Int Paediatrics 1990; 5: 134-141.
16. Evans AM, Faull RJ, Fornasini G, et al. Pharmacokinetics of Lcarnitine in patients with end-stage renal disease undergoing long term haemodiaysis. Clin Pharmacol Ther 2000; 68: 238-249.
17. Wanner C, Horl WH. Carnitine abnormalities in patients with renal insufficiency. Nephron 1988; 50: 89-102.
18. Evans AM, Faull RJ, Nation RL, et al. Impact of HD on endogenous plasma and muscle carnitine levels in patients with end-stage renal disease. Kidney Int 2004; 66: 1527-1534.
19. Evans A. Dialysis related carnitine disorder and levocarnitine pharmacology. Am J Kidney D 2003; 4L: S13-S26.
20. Ahmad S, Robertson HT, Golper TA, et al. (1990) Multi-centre trial of L-carnitine in maintenance haemodialysis patients: Clinical and biochemical effects. Kidney Int 1990; 38: 912-918.
21. Fornasini G, Upton RN, Evans A. A Pharmacokinetic model for Lcarnitine in patient receiving haemodialysis. Br J Clin Pharmacology 2007; 64(3): 335-345.
22. Reuter SE, Evans AM, Faull RJ, Chase DH, Fornasini G. Impact of haemodialysis on individual endogenous plasma acylcarntine concentrations in end-stage renal disease. Ann Clin Biochem 2005; 42: 387-393.
23. De Jong JW, Ferrari R, Eds. The carnitine system. Kluwer, Dordecht 1995.
24. Smith K, Semple D, Aksentijević D, Bhandari S, Seymour AM. Functional and metabolic adaptation in uraemic cardiomyopathy. Frontiers in Bioscience (Elite Edition) 2010; 2: 1942-1501.
25. Barger PM, Kelly DP. Fatty acid utilization in the hypertrophied and failing heart: molecular regulatory mechanisms. Am J Med Sci 1999; 318: 36-42.
26. Fagher B, Cederblad G. Carnitine and left ventricular function in haemodialysis patients. Scan J Clin lab Invest 1985; 45: 193-198.
27. Lopaschuk GD, Belke DD, Gamble J, Itoi T, Schonekess BO. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta 1994; 1212: 263-26.
28. Lango R, Smolenski RT, Narkiewicz M, Suchorzewska J, Lysiak-Szydlowska W. Influence of L-carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass. Cardiovas Res 2001; 51: 21-2.
29. Raine AE, Seymour A-M, Roberts AF, Radda GK, Ledingham JG. Impairment of cardiac function and energetics in experimental renal failure. J Clin Invest 1993; 92: 2934-2940.
30. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Moll Cell Biol 2006; 7: 589-600.
31. Reddy V, Bhandari S, Seymour A-ML. Myocardial function, energy provision and carnitine deficiency in experimental uraemia. J Am Soc Nephrol 2007; 18: 84-92.
32. Broderick TL, Panagakis G, Di Domenico D, et al. L carnitine improvement of cardiac function is associated with a stimulation of glucose but not fatty acid metabolism in carnitine deficient hearts. Cardiovas Res 1995; 30: 815-820.
33. Schonekess BO, Allard MF, Lopaschuk GD. Propionyl-L-carnitine improvement of hypertrophied heart function is accompanied by increase in carbohydrate oxidation. Circ Res 1995; 77: 726-734.
34. Broderick TL, Quinnet HA, Barker CC, Lopashcuk GD. Beneficial effect of carnitine on mechanical recovery of rat hearts reperfused after a transient period of global ischemia is accompanied by a stimulation of glucose oxidation. Circulation 1993; 87: 972-9681.
35. Burton, JO, Jefferies J, Selby NM, McIntyre CW. Haemodialysis - induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function. Clin J Am Soc Nephrol 2009; 4: 1925-1931.
36. Shorofsky SR, Agarwal R, Corretti M, et al. Cellular mechanisms of altered contractility in the hypertrophied heart: big hearts, big sparks. Circ Res 1999; 84: 424-434.
37. Reddy V, Bhandari S, Seymour A-M. Effect of chronic carnitine supplementation on myocardial metabolism and function in uraemia. J Mole Cell Cardiol 2004; 37: 281 (abstract)
38. Leidtke AJ, Vary TC, Nellis SH, Fultz CW. Properties of carnitine in corporation in working swine heart. Effects of coronary flow, ischemia and excess fatty acids. Circ Res 1982; 50: 767-774.
39. Bieber LL, Fiol CJ. Fatty acid and ketone metabolism. Circulation 1985; 72: 5(2) IV9-IV12.
40. Loster H, Keller T, Grommisch J, Grunder W. Effects of Lcarnitine and its acetyl and propionyl esters on ATP and PCr levels in isolated rat heart perfused without fatty acids and investigated by means of 31P-NMR spectroscopy. Moll Cell Biochem 1999; 200: 93-102.
41. Loster H, Miehe K, Punzel M, Stiller O, Pankau H, Schauer J. Prolonged oral L-carnitine substitution increases bicycle ergometer performance in patients with severe, ischemically induced cardiac insufficiency. Cardiovasc Drugs Ther 1999; 13: 537-546.
42. Calvani M, Reda E, Arigoni-Martelli E. Regulation by carnitine of myocardial fatty acid and carbohydrate metabolism under normal and pathological conditions. Basic Res Cardiol 2000; 95: 75-83.
43. Vesela E, Racek J, Trefil L, Jankovy'ch V, Pojer M. Effect of Lcarnitine supplementation in HD patients Nephron 2001, 88: 218-223.
44. Wall BT, Stephens FB, Constantin-Teodosiu D, Macdonald IA, Greenhaff PL. Chronic oral ingestion of L-carnitine and carbohydrate increases muscle carnitine content and alters muscle fuel metabolism during exercise in humans: the dual role of muscle carnitine in exercise metabolism. J Physiol 2002; 10: 1113.
45. Brass EP, Adler S, Sietsema KE, Hiatt WR, Orlando AM, Amato A. Intravenous L-carnitine increases plasma carnitine, reduces fatigue and may preserve exercise capacity in hemodialysis patient. Am J Kidney Dis 2001; 37: 1018-1028.
46. Pauly DF, Pepine CJ. The role of carnitine in myocardial dysfunction. Am J Kidney Dis 2003; 41: S35-S43.
47. Lynch KE, Feldman HI, Berlin JA, Flory J, Rowan CG, Brunelli SM. Effects of L-carnitine on dialysis-related hypotension and muscle cramps: a meta-analysis. Am J Kidney Dis 2008; 52: 962-971.
48. Cherchi A, Lai C, Angelino F, et al. Effects of L-carnitine on exercise tolerance in chronic stable angina: a multicenter, doubleblin, randomized, placebo controlled crossover study. Int J Clin Pharmacol 1985; 23: 569-572.
49. Van Es A, Henny FC, Kooistra MP, Lobatto S, Scholte HR. Amelioration of cardiac function by L-carnitine administration in patients on haemodialysis. Contrib Nephrol 1992; 98: 28-35.
50. Demeyere R, Lormans P, Weidler B, Minten J, Van Aken H, Flameng W. Cardioprotective effects of carnitine in extensive aortocoronary bypass grafting: a double-blind randomised placebo controlled clinical trial. Anesth Analg 1990; 71:520-528.
51. Folts JD, Shug AL, Koke JR. Protection of the ischemic dog myocardium with carnitine. Am J Cardiol 1978; 41: 209-214.
52. Matsumoto Y, Sato M, Ohashi H, et al. Effects of L-carnitrine supplementation on cardiac morbidity in haemodialysis patients Am J Nephrol 2000; 20: 201-217.
53. Romagnoli GF, Naso A, Carraro G and Lidestri V. Beneficical effects of L-carnitine in dialysis patients with impaired left ventricular function: An observational study. Curr Med Res opin 2002; 18: 172-175.
54. Van ES A, Henry FC, Kooistra MP, Lobatto S, Scholte HR. Amelioration of cardiac function by L-carnitine administration in patients on haemodialysis. Contribution to Nephrology 1992; 98: 28-35.
55. Iliceto S, Scrutinio D, Biuzzi P, et al. Effects of L-carnitine administration on left ventricular remodelling after acute anterior myocardial infarction: the L-carnitine (CEDIM) trial. J Am Coll Cardiol 1995; 26: 380-387.
56. Gurlek A, Tutar E, Akcil E, Dincer I, Erol C, Kocatyrk PA, Oral D. Effects of L-carnitine treatment on left ventricular function and erythrocyte superoxide dismutase activity in patients with ischaemic cardiomyopathy. Eur J Heart Fail 2000, 2: 189-193.
57. Rizos I. Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration. Am Heart J 2000; 139: S120-S123.
58. Xue YZ, Wang LX, Lui HZ, Qi XW, Wan XH, Ren HZ. L-carnitine as an adjunct therapy to percutaneous coronary intervention for non-ST elevation myocardial infarction. Cardiovasc Drugs Ther 2007; 21: 445-448.
59. Diaz R, Lorita J, SOley M, Ramirez I. Carnitine worsens both injury and recovery of contractile function after transient ischemia in perfused rat heart. J Physiol Biochem 2008; 64: 1-8.
60. Davini P, Bigalli A, Lamanna F, Boem A. Controlled study on Lcarnitine therapeutic efficacy in post-infarction. Drugs Exp Clin Res 1992; 18: 355-365.
61. Cui J, Das DK, Bertelli A, Tosaki A. Effects of L-carnitine and its derivatives on post ischemic cardiac function, ventricular fibrillation and necrotic and apoptotic cardiomyocyte death in isolated rat hearts. Mol Cell Biochem 2003; 254: 227-234.
62. Gilmour RF Jr, Williams ES, Farner BB, Zippes DP. Effects of carnitine and atractyloside on canine cardiac electrical activity. Am J Physiol 1981; 241: H505-H512.
63. Rebuzzi A, Schiavani G, Amico C, et al. Beneficial effects of Lcarnitine in the reduction of the necrotic area in acute myocardial infarction. Drugs Exptl Clin Res 1984; 10: 219-223.
64. Cherchi A, Lai C, Angelino F, et al. Effects of L-carnitine on exercise tolerance in chronic stable angina: a multicenter, doubleblind, randomized, placebo controlled crossover study. Int J Clin Pharmacol 1985; 23: 569-572.
65. Pastoris O, Dossena M, Foppa P, et al. Effect of L-carnitine on myocardial metabolism: results of a balanced, placebo-controlled, double-blind study in patients undergoing open heart surgery. Pharmacol Res 1998; 37: 115-1222.
66. Singh RB, Niaz MA, Agarwal P, Begum R, Rastogi SS, Sachan DS. A randomised, double-blind, placebo controlled trial of L-carnitine in suspected acute myocardial infarction. Postgrad Med J 1996; 72: 45-50.
67. Cheung AK, Sarnak MJ, Guofen Y, et al. Cardiac diseases in maintenance haemodialysis patients: results of the HEMO study. Kidney Int 2004; 65: 2380-2389.
68. Wanner C, Krane V, Marz W, et al. Atorvostatin in patients with type 2 diabetes mellitus undergoing haemodialysis. N Engl J Med 2005; 353; 238-248.
69. Lopaschuk GD, Hansen CA, Neely JR. Fatty acid metabolism in heart containing elevated levels of CoA. Am J Physiol 1986; 250: H351-H359.
70. Dhalla NS, Kolár F, Shah KR, Ferrari R. Effects of some Lcarnitine derivatives on heart membrane ATPases. Cardiovasc Drugs Ther 1991; 5: 25-30.
71. Sugiyama S, Miyazaki Y, Kotaka K, Kato T, Suzuki S, Ozawa T. Mechanism of free fatty acid-induced arrhythmias. J Electrocardiol 1982; 15: 227-232.
72. Oliver MF, Kurien VA, Greenwood TW. Relation between serum free fatty acids and arrhythmias and death after acute myocardial infarction. Lancet 1968; 1: 710-714.
73. Duan JM, Moffat MP. Protective effects of phosphatidylcholine against mechanisms of ischemia and reperfusion-induced arrhythmias in isolated guinea pig ventricular tissues. Naunyn Schmiedebergs Arch Pharmacol 1991; 342: 342-348.
74. Imai S, Matsui K, Nakzawa M, Takatsuka, Takeda A, Tamatsu H. Anti-arrythmic effects of L-carnitine chloride and it acetyl analogue on canine late ventricular arrhythmia induced by ligation of the coronary artery as related to improvement of mitochondrial function. Br J Pharmacol 1984; 82: 533-542.
75. Cui J, Das DK, Bertelli, Tosaki A. Effects of L-carntiine andits derivatives on postischemic cardiac function, ventricular fibrillation and necrotic and apoptotic cardiomyocyte death in isolated rat hearts. Mole Cell Biochem 2003; 254: 227-234.
76. Rizzon P, Biasco G, Di Biase M, et al. High doses of L-carnitine in acute myocardial infarction: metabolic and anti-arrhythmic effects. Eur Heart J 1989; 19:551-554.
77. Fricke L, Preuss R, Santjer G, Diedrich KW, Shultz E, Sack K. Effects of a replacement therapy with L-carnitine on arrhythmia, echocardiographic parameters and the clinical health in hemodialysed patients with cardiomyopathy. Nieren und Hochdruckkrankheiten 1988; 17: 114-119.
78. Chazot C, Blanc C, Hurot JM, Charra B, Jean G, Laurent G. Nutritional effects of carnitine supplementation in hemodialysis patients. Clin Nephrol 2001; 59: 24-30.
79. Paulson DJ, Shug AL. Effects of carnitine on the ischemic arrested heart. Basic Res Cardiol 1982; 77: 460-463.
80. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uraemia. NDT 1996; 11: 1277-1285.
81. Ferrari R, Ceconi CD, Cardnoni A, et al. The effect of Lpropionylcarnitine on the ischaemic and reperfued intact myocardium and on their derived mitochondria. Cadiovasc Drugs Ther 1991; 5: 57-66.
82. Kudoh Y, Shoji T, Oimatsu H, Yoshida S, Kikuchi K, Iimura I. The role of carnitine in the pathogenesis of cardiomegaly in patients with chronic hemodialysis. Jpn Circulation J 1983; 47: 1391-1397.
83. Kooistra MP, Struyvenberg A, van Es A. The response to recombinant human erythropoetin in patients with anemia of endstage renal disease is correlated with serum carnitine levels. Nephron 1991; 57: 127-128.
84. Labonia WD. L-carnitine effects on anaemia in HD patients treated with EPO. Am J Kidney Dis 1995; 26: 757-764.
85. Trovato GM, Ginardi V, Di Marco V, et al. Long term L-carnitine treatment of chronic anaemia of patients with end-stage renal failure. Curr Ther Res 1982; 31: 1042-1043.
86. Reuter SE, Faull RJ, Ranieeri E, Evasn AM. Endogenous plasma carnitine pool composition and response to erythropoietin treatment in chronic haemodialysis patient. Nephrol Dial Transplant 2009; 24: 990-996.
87. Vlassopoulos DA, Hadiuannakos DK, Anogiatis AG, et al. Carnitine action on red blood cell osmotic resistance in hemodialysis patients. J Nephrol 2002; 15: 68-73.
88. Sotirakopoulos N, Athanastou G, Tsitsios T, et al. Effect of Lcarnitine supplementation on red blood cell deformability in haemodialysis patients. Ren Fail 2000; 22: 73-80.
89. Farrington K, Hodsman A, Casula A, Ansell D, Feehally J. UK Renal Registry report 2008, in chapter4: ESRD prevalent rates in 2007 in the UK; national and centre-specific analyses, UK Renal registry, UK, pp. 43-68.
90. Bellinghieri G, Savica V, Mallamace A, et al. Correlation between increased serum and tissue L-carnitine levels and improved muscle symptoms in hemodialyzed patients. Am J Clin Nutr 1983; 38(4): 523-531.
91. Siami G, Clinton ME, Mrak R, Griffis J, Stone W. Evaluation of the effect of intravenous L-carnitine therapy on function, structure and fatty acid metabolism of skeletal muscle in patients receiving chronic hemodialysis. Nephron 1991; 57: 306-313.
92. Eknoyan G, Latos DL, Lindberg J. Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder. National Kidney Foundation Carnitine Consensus Conference. Am J Kidney Dis 2003; 41(4): 868-876.
93. National Kidney Foundation: K/DOQI Clinical Practice Guidelines and Clinical Practice recommendations for anaemia in Chronic Kidney Disease in Adults: II. Am J Kidney Dis 2006; 47: S1.